21861 U.S 032604

UTILITY PATENT APPLICATION TRANSMITTAL

(only for new non-provisional applications under 37 CFR §1.53(b))

Mail Stop Patent Application Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Transmitted herewith for filing is the patent application under 37 CFR 1.53(b) of:

AVENTIS DOCKET NO.: FRAV2003/0007 US

INVENTORS: Antony Bigot, et al

TITLE: 4-Substituted Quinoline Derivatives,
Method And Intermediates For Their Preparation
And Pharmaceutical Compositions Containing Them

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

Date of Deposit

EL964823123US

Express Mail No

16834 U.S. PTO 10/810711

_					
Λ	DDI		α		JENTS
м	FFL	JUALI	UN	ELEI	MEIAIS

1.	\boxtimes	*Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing)		
2.		Specification (preferred arrangement set forth below) - Descriptive title of the Invention - Cross References to Related Applications - Statement Regarding Fed sponsored R & D - Reference to Microfiche Appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure	Total Pages	96
3.		Drawing(s) (35 U.S.C. 113)	Total Sheets	
4.	Oath a.	or Declaration Unexecuted (original or copy)	Total Pages	2
	b.	Copy from a prior application (37 CFR § 1	.63(d))	
		i. DELETION OF INVENTOR(S) Signed statement attached deleting is application, see 37 CFR §§ 1.63(d)(2)		ned in the prio
5.	Powe	er of Attorney	Total Pages	
	a.	Newly executed (original or copy)		
	b.	Copy from a prior application (37 CFR § 1	.63(d))	
6.		Microfiche Computer Program (Appendix)		

Page					
7.	Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. Computer Readable Copy b. Paper Copy (identical to computer copy) c. Statement verifying identity of above copies				
	If a CONTINUING Application, check appropriate box, and supply the requisite information: Continuation Divisional Continuation-in-part of prior application no:, filed, Examiner, Group/Art Unit (The cross reference has been/will be inserted on page one of the specification).				
	This application claims the benefit of U.S. Provisional Application No. 60/487,084, filed July 14, 2003, and claims priority of French Application No. 0303812 filed March 28, 2003. (The cross reference has been/will be inserted on page one of the specification).				
	Incorporation By Reference (useable if filing a continuation/divisional and a copy of the declaration from the prior application is enclosed.) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.				
ACC	OMPANYING APPLICATION PARTS				
7. 8. 9.	Assignment Papers (cover sheet & document(s)) 37 CFR §3.73(b) Statement (when there is an assignee) Verified English Translation Document (if applicable)				
10.	Information Disclosure Copies of IDS Citations Statement (IDS)/PTO-1449				
11. 12.	Preliminary Amendment Return Receipt Postcard (MPEP 503) (Should be expecifically itemized)				
13.	(Should be specifically itemized) *Small Entity Statement(s) (PTO/SB/09-12) Status still proper and desired				
14.	Certified Copy of Priority Document(s) 0303812 (if foreign priority is claimed)				
15.	Other: Application Data Sheet				
COR	RESPONDENCE ADDRESS				
\boxtimes	Customer Number or Bar Code Label 005487				
	(Insert Customer No. or Attach bar code label here)				
	Joseph Strupczewski Reg. No. 50,903				

Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc. Patent Department Route #202-206 / P.O. Box 6800 Bridgewater, New Jersey 08807-0800 Telephone (908) 231-2387 Telefax (908) 231-2626 Aventis Docket No. FRAV2003-0007 US NP

FRAV2003-0007 US NP

Complete (If applicable)

Telephone

(908) 231-2387

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Attorney Docket No.

FEE TRANSMITTAL	Complete if Known		
LEE I LANSIVII I AL	Application Number	Not Yet Assigned	
(- F)/ 0004	Filing Date	Concurrently Filed Herewi	
for FY 2004	First Named Inventor	Antony Bigot, et al	
Patent fees are subject to annual revision.	Examiner Name		
Applicant claims small entity status. See 37 CFR 1.27	Group / Art Unit		

(\$) 770.00

METHOD OF PAYMENT (check all that apply)	FEE CALCULATION (continued)				
Check Credit Card Money Other None	3. Al	ODITIO	NAL F	EES	· · · · · · · · · · · · · · · · · · ·
Order Deposit Account	Large E	ntity	Small E	ntity	
Deposit	Fee Code	Fee (\$)	Fee Code	Fee (\$)	
Account Number 18-1982 Deposit		(4)	Code	(4)	Fee Description Fee Pald
Account Aventis Pharmaceuticals Inc.	1051	130	2051	65	Symbology lots files for a soft
The Commissioner is authorized to: (check all that apply)					Surcharge - late filing fee or oath Surcharge - late provisional filing fee or
Charge fee(s) indicated below Credit any overpayments	1052 1053	50 130	2052 1053	25 130	cover sheet Non-English Specification
Charge any additional fee(s) during the pendency of this application	1812	2,520	1812	2,520	For filing a request for reexamination
Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account	1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action
FEE CALCULATION	1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action
1. BASIC FILING FEE	1251	110	2251	55	Extension for reply within first month
Large Entity Small Entity Fee Fee Fee Fee Fee Description Code (\$) Code	1252	420	2252	205	Extension for reply within second month
1001 770 2001 375 Utility filing fee 770	1253	950	2253	465	Extension for reply within third month
1002 340 2002 165 Design filing Fee	1254	1,480	2254	725	Extension for reply within fourth month
1003 530 2003 260 Plant filing fee	1255	2,010	2255	985	Extension for reply within fifth month
1004 770 2004 375 Reissue filing fee	1401	330	2401	160	Notice of Appeal
1005 160 2005 80 Provisional filing fee	1402	330	2402	160	Filing a brief in support of an appeal
SUBTOTAL (1) (\$) 770.00	1403	290	2403	140	Request for oral hearing
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE	1451	1,510	1451	1,510	Petition to institute a public use proceeding
Fee Extra from Fee	1452	110	2452	55	Petition to revive - unavoidable
Claims below Paid	4.50	4 000	0450	050	Balling to the second s
Total Claims 15 -20**= 0 x 18 = 0	1453	1,330	2453	650	Petition to revive - unintentional
ndependent 3 - 3**= 0 x 86 = 0	1501	1,330	2501	650	Utility issue fee (or reissue)
Claims	1502 1503	480 640	2502 2503	235 315	Design issue fee Plant issue fee
Multiple Dependent 0 = 0	1460	130	1460	130	Petitions to the Commissioner
Large Entity Small Entity	1807	50	1807	50	Petitions related to provisional
Fee Fee Fee Code (\$) Code (\$) Fee Description					applications
Code (\$) Code (\$) Fee Description 1202 18 2202 9 Claims in excess of 20	1806	180	1806	180	Submission of Information Disclosure
1201 86 2201 42 Independent claims in excess of 3	8021	40	8021	40	Recording each patent assignment per property (times number of properties)
1203 290 2203 140 Multiple dependent claim, if not paid	1809	770	2809	375	Filing a submission after final rejection (37 CFR § 1.129(a))
1204 86 2204 42 **Reissue independent	1810	770	2810	375	For each additional invention to be
claims over original patent 1205 18 2205 9 **Reissue claims in excess of 20 and over original patent	1801	770	2801	375	examined (37 CFR § 1.129(b)) Request for Continued Examination (RCE)
,	1802	900	1802	900	Request for expedited examination of a design application
SUBTOTAL (2) (\$) 0.00	Other fee	(specify)			acoign approaudit
**or number previously paid, if greater, For Reissues, see above	*Reduce	d by Basic	: Filing Fee	e Paid	SUBTOTAL (3) (5)

Signature (Attorney/Agent)

Date 03/26

WARNING: Information on this form may become public. Credit card information should not be

Registration No.

50,903

included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office.

Joseph Strupczewski, Reg. No. 50,903

SUBMITTED BY

Name (Print/Type)

TOTAL AMOUNT OF PAYMENT